Variability of transdermal fentanyl metabolism and excretion in pain patients

Journal of Opioid Management

Volumn 6, Issue 1, 2010, Pages 29-39

  Cole, Joanna M ^a   Best, Brookie M ^a,b   Pesce, Amadeo J ^c,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c Millennium Laboratories of California Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Excretion; Fentanyl patch; Metabolism

Indexed keywords

FENTANYL;

ARTICLE; CHRONIC PAIN; CLINICAL ASSESSMENT; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCUBATION TIME; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PRESCRIPTION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TRANSDERMAL PATCH; URINALYSIS;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; FENTANYL; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; PAIN; PAIN MEASUREMENT; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 77949520064     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2010.0002     Document Type: Article

References (30)

1. Muijsers RBR, Wagstaff AJ: Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001; 61: 2289-2307.
2. Duragesic: Fentanyl transdermal system [full prescribing information]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, July 2009. Available at https://www.ortho-mcneil.com/ ortho-mcneil/shared/pi/duragesic.pdf. Accessed August 20, 2009.
3. Alonso-Zaldivar R: FDA renews warning for powerful painkiller patch - The agency says the drug has been misused and wrongly prescribed. Los Angeles Times. December 22, 2007. Available at http://articles.latimes.com/2007/ dec/22/nation/na-patch22. Accessed August 4, 2009.
4. Lamb E: Top 200 drugs of 2008. Pharmacy Times. May 15, 2009. Available at http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/ RxFocusTop200Drugs-0509. Accessed August 5, 2009.
5. Moore TJ, Cohen MR, Furberg CD: Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007; 167: 1752-1759.
6. Schneider E, Brune K: Opioid activity and distribution of fentanyl metabolites. Naunyn Schmiedebergs Arch Pharmacol. 1986; 334: 267-274.
7. Poklis A, Backer R: Urine concentrations of fentanyl and norfentanyl during application of duragesic transdermal patches. J Anal Toxicol. 2004; 28: 422-425.
8. Labroo RB, Paine MF, Thummel KE, et al.: Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997; 25: 1072-1080.
9. Goromaru T, Matsuura H, Yoshimura N, et al.: Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography-mass spectrometry. Anesthesiology. 1984; 61: 73-77.
10. Tateishi T, Krivoruk Y, Ueng Y-F, et al: Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996; 82: 167-172.
11. Feierman DE, Lasker JM: Metabolism of fentanyl, a synthetic opioid analgesic by human liver microsomes: Role of CYP3A4. Drug Metab Dispos. 1996; 24: 932-939.
12. Guitton J, Buronfosse T, Désage M, et al.: Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol. 1997; 53: 1613-1619.
13. Jin M, Gock SB, Jannetto PJ, et al.: Pharmacogenomics as molecular autopsy for forensic toxicology: Genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005; 29: 590-598.
14. Mikel C, Almazan P, West R, et al.: LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit. 2009; 31: 746-748.
15. Solassol I, Bressolle F, Caumette L, et al.: Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hr transdermal applications in cancer pain patients. Ther Drug Monit. 2005; 27: 491-498.
16. Portenoy RK, Southam MA, Gupta SK, et al.: Transdermal fentanyl for cancer pain: Repeated dose pharmacokinetics. Anesthesiology. 1993; 78: 36-43.
17. Durcan TG, Sockalingham I, Hanna MH, et al.: Pharmacokinetic study of repeated 72 hour applications of TTS-fentanyl. Br J Anaesth. 1995; 74(Suppl 1): 139.
18. Larsen RH, Nielsen F, Sørensen JA, et al.: Dermal penetration of fentanyl: Inter- and intraindividual variations. Pharmacol Toxicol. 2003; 93: 244-248.
19. Sera S, Goromaru T, Sameshima T, et al.: Individual variations in the elimination process of fentanyl in patients. Xenobiol Metabol Dispos. 2000; 15: 495-503.
20. Varvel JR, Shafer SL, Hwang SS, et al.: Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989; 70: 928-934.
21. Gourlay GK, Kowalski SR, Plummer JL, et al.: The transdermal administration of fentanyl in the treatment of postoperative pain: Pharmacokinetics and pharmacodynamic effects. Pain. 1989; 37: 193-202.
22. Van Bastelaere M, Rolly G, Van Peer A: Pharmacokinetic behaviour of transdermal fentanyl. Br J Anaesth. 1993; 70(Suppl 1): 75.
23. Reilly CS, Wood AJJ, Wood M: Variability of fentanyl pharmacokinetics in man: Computer predicted plasma concentrations for three intravenous dosage regimens. Anaesthesia. 1984; 40: 837-843.
24. Kokubun H, Matoba M, Hoka S, et al.: Relationship between serum fentanyl concentration and transdermal fentanyl dosage, and intra-individual variability in fentanyl concentration after application of fentanyl patches in patients with cancer pain. Jpn J Pharm Health Care Sci. 2007; 33: 200-205.
25. Anderson DT, Muto JJ: Duragesic transdermal patch: Postmortem tissue distribution of fentanyl in 25 cases. J Anal Toxicol. 2000; 24: 627-634.
26. Murphy MR, Hug CC Jr, McClain DA: Dose-independent pharmacokinetics of fentanyl. Anesthesiology. 1983; 59: 537-540.
27. Ashburn MA, Ogden LL, Zhang J, et al.: Pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003; 4: 291-297.
28. Norfentanyl: SciFinder [database online]. Washington, DC: The American Chemical Society, 2009. Available at https://scifinder.cas.org/ scifinder/view/substance/substanceExplore.jsf. Accessed August 19, 2009.
29. Cicero TJ, Inciardi JA, Surratt H: Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug Alcohol Depend. 2007; 91(2-3): 115-120.
30. Fodale V, Mafrica F, Santamaria LB, et al.: Killer fentanyl: Is the fear justified [editorial]? Expert Opin Drug Saf. 2008; 7: 213-217.